AstraZeneca Says $3.5bn Brilinta Sales Forecast By 2023 Now Unattainable

04 Oct 2016

• By Sten Stovall

AstraZeneca will cut its sales forecasts for Brilinta after the therapy failed to beat the older blood thinner clopidogrel in the comparison EUCLID study in peripheral artery disease.

AstraZeneca Says $3.5bn Brilinta Sales Forecast By 2023 Now Unattainable

More from Clinical Trials

More from R&D